Repositorio Dspace

The safety and clinical effectiveness of rapid infusion with CT-P10 in patients with non-Hodgkin's lymphoma or chronic lymphocytic leukemia: A retrospective non-interventional post-authorization safety study in Europe

Mostrar el registro sencillo del ítem

dc.contributor.author Bishton, Mark
dc.contributor.author Marshall, Scott
dc.contributor.author Harchowal, Jatinder
dc.contributor.author Salles, Gilles
dc.contributor.author Golfier, Camille
dc.contributor.author Tucci, Alessandra
dc.contributor.author Rodríguez-Fernández, Alicia
dc.contributor.author Sánchez-Blanco, José-Javier
dc.contributor.author Bocchia, Mónica
dc.contributor.author Kim, SooKyoung
dc.contributor.author Lee, Young-Nam
dc.contributor.author Zinzani, Pier-Luigi
dc.date.accessioned 2025-11-18T09:28:14Z
dc.date.available 2025-11-18T09:28:14Z
dc.date.issued 2022-08
dc.identifier.citation Bishton M, Marshall S, Harchowal J, Salles G, Golfier C, Tucci A, et al. The safety and clinical effectiveness of rapid infusion with CT-P10 in patients with non-Hodgkin¿s lymphoma or chronic lymphocytic leukemia: A retrospective non-interventional post-authorization safety study in Europe. Hematological Oncology. agosto de 2022;40(3):370-80.
dc.identifier.issn 0278-0232
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/20750
dc.description.abstract Rapid infusion (RI) of the rituximab biosimilar CT-P10 is currently only an approved treatment regimen for the treatment of rheumatoid arthritis. Although both CT-P10 and reference rituximab are known to be frequently administered using a RI regimen (¿90 min) in clinical practice, published data on the safety of RI of CT-P10 in patients with NHL and CLL are limited. Hence, this study collected real-world safety and effectiveness data on RI-CT-P10 from the medical records of 196 patients with NHL or CLL in 10 European centers, 6 months after the date of the first RI (index date); the infusion-related reaction (IRR) rate was compared to previously published data. Ten percent (95% confidence interval 6%-15%; n = 20/196) of patients experienced an infusion-related reaction (IRR) on day 1-2 post-index, which was not significantly different (p = 0.45) to the IRR rate for rituximab described in a previous meta-analysis (8.8%). During the observation period, 2% of patients experienced grade 3-5 IRRs and 85% (n = 166) experienced an adverse event (non-IRR). The most common reason for discontinuation of first-line CT-P10 was planned treatment completion (81%; n = 158). Complete response and partial response to CT-P10 was observed in 74% (n = 142/192) and 22% (n = 42/192) of patients, respectively. The results of this real-world study demonstrate that the safety and effectiveness profile of RI-CT-P10 is similar to RI of reference rituximab and therefore support the current use of RI-CT-P10 in patients with NHL and CLL.
dc.language.iso eng
dc.publisher Wiley
dc.subject.mesh Antibodies, Monoclonal, Murine-Derived
dc.subject.mesh Biosimilar Pharmaceuticals/adverse effects
dc.subject.mesh Drug-Related Side Effects and Adverse Reactions
dc.subject.mesh Humans
dc.subject.mesh Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy
dc.subject.mesh Lymphoma, Non-Hodgkin/drug therapy
dc.subject.mesh Retrospective Studies
dc.subject.mesh Rituximab/adverse effects
dc.subject.mesh Treatment Outcome
dc.title The safety and clinical effectiveness of rapid infusion with CT-P10 in patients with non-Hodgkin's lymphoma or chronic lymphocytic leukemia: A retrospective non-interventional post-authorization safety study in Europe
dc.type info:eu-repo/semantics/article
dc.identifier.pmid 35168291
dc.relation.publisherversion https://onlinelibrary.wiley.com/doi/10.1002/hon.2978
dc.identifier.doi 10.1002/hon.2978
dc.journal.title Hematological Oncology
dc.identifier.essn 1099-1069


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta